{"classes":[{"categories":[{"measurements":[{"comment":"NA = OS upper limit was not reached (insufficient number of deaths by time of last disease assessment).","groupId":"OG000","lowerLimit":"7.3","upperLimit":"NA","value":"22.3"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"18.1","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"OS was defined as the time from the first dose to death due to any cause. OS is presented from product limit (Kaplan-Meier) method for censored data (censored at the last assessment).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"},{"description":"Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG001","title":"Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who received at least one dose of study medication (pembrolizumab).","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months (Database Cutoff Date: 28MAY2019)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}